I am experiencing urinary retention that began before I started glycopyrrolate for hyperhidrosis (while also taking quetiapine); how should I evaluate and manage this condition?

Urinary Retention Pre-Dating Glycopyrrolate: Evaluation and Management

Your urinary retention that began before starting glycopyrrolate is most likely caused by quetiapine, which has well-documented anticholinergic effects that impair bladder emptying, and you should immediately discuss discontinuing or switching this medication with your prescriber while avoiding the addition of glycopyrrolate until the retention resolves.

Primary Culprit: Quetiapine

The evidence strongly implicates quetiapine as your problem:

• Quetiapine carries significant risk for urinary retention through its anticholinergic properties that inhibit bladder contraction 1, 2
• A systematic review found quetiapine had higher odds of causing voiding dysfunction than other atypical antipsychotics (OR: 2.14; 95% CI: 1.41-3.26) 2
• A case report documented a patient who developed urinary retention on quetiapine 600mg (similar dosing range) requiring 19 months of intermittent catheterization, with normal function returning only 3 days after stopping the medication 3
• Antipsychotics cause both storage and emptying disorders, with voiding dysfunction being particularly common 2

Critical Contraindication for Glycopyrrolate

Do not start glycopyrrolate while experiencing urinary retention:

• The FDA label explicitly lists "problems urinating" as an absolute contraindication to glycopyrrolate 4
• Glycopyrrolate causes urinary retention as a known adverse effect through its anticholinergic mechanism 4, 5
• Adding glycopyrrolate to existing retention would compound the problem through additive anticholinergic effects

Immediate Management Steps

1. Medication Review (Priority Action)

• Contact your prescriber immediately to discuss quetiapine discontinuation or dose reduction
• Consider switching to an antipsychotic with lower anticholinergic burden
• The case report showed resolution within 3 days of stopping quetiapine 3

2. Urological Evaluation

Assess for other contributing factors:

• Post-void residual (PVR) measurement - quantifies retention severity
• Rule out benign prostatic hyperplasia (if male) - common co-contributor in older patients 6, 7
• Assess for neurogenic bladder or anatomical obstruction
• Document baseline bladder function before any medication changes

3. Symptomatic Management

If retention is severe (inability to void, bladder distension, pain):

• Urinary catheterization may be necessary for acute relief 8
• Alpha-blockers (e.g., tamsulosin, alfuzosin) can facilitate voiding if there's concurrent prostatic obstruction 9

Key Clinical Pitfalls

Common mistakes to avoid:

• Never add anticholinergic medications (like glycopyrrolate) to existing urinary retention - this is contraindicated and will worsen the condition 4
• Don't assume retention will resolve spontaneously while continuing the offending medication - the case report showed 19 months of dysfunction 3
• Elderly patients and those with low BMI are at higher risk for anticholinergic side effects 3, 6
• Multiple anticholinergic medications have additive effects - review all medications for anticholinergic burden 6

Prognosis

The evidence suggests urinary retention from quetiapine is reversible upon discontinuation:

• Normal function typically returns within days of stopping the medication 3
• However, prolonged retention can occur if the medication is continued 3

Alternative Approach for Hyperhidrosis

Once urinary retention resolves:

• Re-evaluate need for glycopyrrolate
• Consider non-anticholinergic alternatives for hyperhidrosis
• If glycopyrrolate is essential, ensure complete resolution of retention and close monitoring with PVR measurements 10, 9

Bottom line: Your quetiapine is the likely cause of your urinary retention, glycopyrrolate is contraindicated in your current state, and medication adjustment is urgently needed to prevent long-term bladder complications.